Literature DB >> 9796067

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.

A Sjölander1, T M Baldwin, J M Curtis, K L Bengtsson, E Handman.   

Abstract

Vaccination with the native Parasite Surface Antigen 2 of Leishmania major with Corynebacterium parvum as adjuvant protects mice from leishmaniasis through a Th1 mediated response. Here we show that vaccination with a recombinant form of this protein, purified from Escherichia coli and administered in iscoms or with C. parvum as adjuvant, does not induce protective immunity despite the induction of Th1 responses. The results suggest that protective immunity depends on the ability of the vaccinating antigen to induce Th1-like T cells with ability to be recalled by infection. Therefore, the conformation of antigens may play a more major role for the induction of T cell mediated immunity than originally considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796067     DOI: 10.1016/s0264-410x(98)00075-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Proteoliposomes in nanobiotechnology.

Authors:  P Ciancaglini; A M S Simão; M Bolean; J L Millán; C F Rigos; J S Yoneda; M C Colhone; R G Stabeli
Journal:  Biophys Rev       Date:  2012-01-18

3.  Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

Review 5.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

6.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 7.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

8.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

9.  DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.

Authors:  Kimberly Campbell; Hong Diao; Jiaxiang Ji; Lynn Soong
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.

Authors:  Rhea N Coler; Yasuyuki Goto; Lisa Bogatzki; Vanitha Raman; Steven G Reed
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.